Food and Drug Administration gives approval to Synjardy XR tablets
Synjardy XR tablets were developed to treat type 2 diabetes in adult patients. Synjardy XR, when used in combination with diet and exercise, can improve blood sugar levels in adult patients who have type 2 diabetes when empagliflozin and metformin are taken.
"Adults with type 2 diabetes often take multiple medications, sometimes more than once a day, to manage their condition," Boehringer Ingelheim Pharmaceuticals President and CEO Paul Fonteyne said. "With Synjardy XR, the eighth FDA-approved treatment to emerge from our partnership with Lilly, adults with type 2 diabetes now have another convenient daily option to help them reach their glycemic goals, whether they are already being treated or are just at the beginning of their treatment."
Synjrady XR consists of a combination if empagliflozin and metformin. These two drugs are complementary mechanisms of action for one another and help to blood glucose improvement in type 2 diabetes patients.
The FDA’s approval of Synjardy XR tablets is due to a number of clinical trials that assessed both empagliflozin and metformin.
Synjardy XR is marketed by Eli Lilly and Boehringer Ingelheim.
Organizations in this story
Eli Lilly and Company 1555 S Harding St Indianapolis, IN - 46221